Roche collaborates with Eli Lilly to enhance early diagnosis of Alzheimer's disease
Basel: Roche has announced that it has entered into a collaboration with Eli Lilly and Company to support the development of Roche’s Elecsys Amyloid Plasma Panel (EAPP). The EAPP is a blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease.
Today, barriers to early and accurate diagnosis of Alzheimer’s exist across the globe with up to 75% of people living with the symptoms of Alzheimer’s, but without a diagnosis. Those who have received a diagnosis waited, on average, 2.8 years after symptom onset. To address the growing strain that Alzheimer’s is putting on healthcare systems, it will be essential to make a person's journey to diagnosis faster and more accessible. This will ultimately enable access to appropriate new therapies as they become available.
"This collaboration is aligned with both Roche and Lilly’s shared objective to support patients by improving the journey to a timely and accurate diagnosis and treatment. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis," the release stated.
“We are excited to be collaborating with Lilly on such an important area of unmet medical need,” said Matt Sause, CEO of Roche Diagnostics. “Today, over 55 million people are living with dementia and this is projected to increase to nearly 140 million by 20502. Collaboration is essential to ensure these people receive a timely and accurate diagnosis. The Elecsys Amyloid Plasma Panel has the potential to streamline a person's journey to diagnosis and, therefore, access to future treatment options.”
"We are pleased to be joining Roche to support the development of yet another potential diagnostic tool,” said Mark Mintun, Lilly group vice president – Neuroscience R&D and president, Avid Radiopharmaceuticals. "We look forward to the robust data and continued collaboration across the field that will be critical to accelerate the ecosystem to aid in a timely and accurate diagnosis of Alzheimer’s."
In July, Roche announced that the U.S. Food and Drug Administration granted the EAPP Breakthrough Device Designation.
In December 2022, Roche also received FDA 510(k) clearance for its Elecsys beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys Phospho-Tau (181P) CSF (pTau181) assays, which identify Alzheimer's pathology in its early symptomatic stage.
